NSE: DIVISLAB | BSE: 532488

Expensive Star

Download real time

9619.50 17.50 (0.18%)

New 52W High in past week

404.6K NSE+BSE Volume

NSE 25 Sep, 2026 3:31 PM (IST)

255,367.5

Market Cap

Market Runner Up

Beta 1Year

Very Low volatility

Divi's Laboratories Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for DIVISLAB, BSE:532488 Divi's Laboratories Ltd.

Search Inside the pdf :

Divi's Laboratories Ltd.

04 Aug 2026

9619.50

0.18%

Outlook

Hold: Divi's Laboratories Ltd.

Target

Deven Choksey

Divi's Laboratories' outlook remains positive, supported by a healthy pipeline of custom synthesis projects, continued expansion in peptides, and the gradual commercialization of contrast media products.

Divi's Laboratories has gained 63.13% in the last 1 Year

Divi's Laboratories Ltd.

02 Aug 2026

9619.50

0.18%

CDMO execution drives earnings beat

Neutral: Divi's Laboratories Ltd.

Target

Motilal Oswal

Divi’s Lab (DIVI) delivered higher-than-estimated financial performance for 1QFY27, with a 12%/40%/37% beat on revenue/EBITDA/PAT. Strong traction in the custom synthesis business led to an earnings surprise for the quarter.

Divi's Laboratories has gained 43.29% in the last 3 Months

Divi's Laboratories Ltd.

08 Jul 2026

9619.50

0.18%

Divis Laboratories Ltd – Q1FY27 Preview:

Accumulate: Divi's Laboratories Ltd.

Target

Deven Choksey

We expect the company to grow its Revenue/EBITDA/PAT at a CAGR of 15.3% / 20% / 18.2% for the period of FY26-FY28.

Divi's Laboratories has gained 59.94% in the last 6 Months

Divi's Laboratories Ltd.

28 May 2026

9619.50

0.18%

Valuation

Accumulate: Divi's Laboratories Ltd.

Target

Deven Choksey

We expect the company to grow its Revenue/EBITDA/PAT at a CAGR of 15.3% / 20% / 18.2% for the period of FY26-FY28.

Divi's Laboratories has gained 43.29% in the last 3 Months

Divi's Laboratories Ltd.

25 May 2026, 12:00AM

9619.50

0.18%

Divi's Laboratories (DIVI IN) Q4FY26 Result Update EBITDA miss; Peptide opportunities key for growth ACCUMULATE

Accumulate: Divi's Laboratories Ltd.

Target

Prabhudas Lilladhar

Divi's Laboratories (DIVI) Q4FY26 EBITDA missed our estimates due to lower gross margin. Revenues were largely aided by CS segment and currency tailwind. Mgmt indicated inventory levels may increase further in Q1FY27E to ensure uninterrupted operations. We expect stable margins in FY27 and expect revenue to accelerate from FY28 as commencement of some CDMO and contrast media contracts along with peptide revenue scale up. Our FY27E/FY28E EPS estimates stand cut by 2-4%. We expect 19% EBITDA and PAT CAGR over FY26-28E. At CMP, stock is trading at 52x...

Divi's Laboratories .. has an average target of 7062.83 from 6 brokers.

Divi's Laboratories Ltd.

24 May 2026

9619.50

0.18%

Divi's Labs (HOLD): Margin headwinds to persist in near term

Hold: Divi's Laboratories Ltd.

Target

BOB Capital Markets Ltd.

Sales/EBITDA /PAT reported 3.4%/10%/1 below our estimates. EBITDA Margin was reported 235 bps below our estimates at 33%

Divi's Laboratories has gained 43.29% in the last 3 Months

Divi's Laboratories Ltd.

06 Apr 2026

9619.50

0.18%

DIVI' S LAB

Hold: Divi's Laboratories Ltd.

Recommendation Target

Geojit BNP Paribas

The outlook remains positive, supported by Divi's strong positioning in custom synthesis and a diversified pipeline, with management highlighting active engagement with global innovator customers and multiple projects progressing through development and validation. Ongoing capacity additions along with a focus on disciplined execution and supply reliability are expected to support future growth, while the nutraceuticals business continues to provide healthy momentum and diversification. The company has also completed construction of a dedicated peptide facility, strengthening its capabilities in this fast-evolving segment, and...

Divi's Laboratories has gained 59.94% in the last 6 Months

Divi's Laboratories Ltd.

20 Nov 2025

9619.50

0.18%

Healthy CS traction and favorable mix boosted profitability even as generics remained soft

Accumulate: Divi's Laboratories Ltd.

Target

Deven Choksey

Divi’s enters the second half of FY26 with a healthy execution pipeline across Custom Synthesis, supported by multiple projects progressing through validation and expected to commercialize over the next 1–2 years.